“The performance last year marked a significant step forward for AstraZeneca. Despite the significant impact from the pandemic, we delivered double-digit revenue growth to leverage improved profitability and cash generation. The consistent achievements in the pipeline, the accelerating performance of our business and the progress of the COVID-19 vaccine demonstrated what we can achieve, while the proposed acquisition of Alexion is intended to accelerate our scientific and commercial evolution even further.

Additional investment in new medicines continued to fuel our rapidly growing oncology and biopharmaceuticals therapy areas. Tagrisso’s future was enhanced with its first regulatory approval in early, potentially-curable lung cancer and further national reimbursement in China in advanced disease. Farxiga again expanded its potential beyond diabetes, while tezepelumab promised real hope for patients suffering from severe asthma. Thanks to the focus on an industry-leading pipeline and consistent execution, I am confident that we will continue to deliver more progress for patients and sustained, compelling results.”

Pascal Soriot
Chief Executive Officer

---

### Financial highlights

#### Total Revenue*
- Up 9% at actual rate of exchange to $26,617 million (up 10% at CER), comprising Product Sales of $25,890 million (up 10%; 11% at CER) and Collaboration Revenue of $727 million (down 11%; 11% at CER)

#### Net cash flow from operating activities
- Up 62% at actual rate of exchange to $4,799 million

#### Reported operating profit
- Up 77% at actual rate of exchange to $5,162 million (up 81% at CER)

#### Core operating profit
- Up 14% at actual rate of exchange to $7,340 million (up 17% at CER)

#### Reported EPS
- Up 137% at actual rate of exchange to $2.44 (up 142% at CER)

#### Core EPS
- Up 15% at actual rate of exchange to $4.02 (up 18% at CER)

---

* As detailed from page 181 of the 2020 Annual Report, Total Revenue consists of Product Sales and Collaboration Revenue.

---

// Denotes a scale break. Throughout this Annual Report, all bar chart scales start from zero. We use a scale break where charts of a different magnitude, but the same unit of measurement, are presented alongside each other.
Inspired by our Values and what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients and society.

Our strategic priorities

Our priorities reflect how we are working to deliver our growth through innovation strategy and achieve our Purpose: to push the boundaries of science to deliver life-changing medicines.

1. Deliver Growth and Therapy Area Leadership
2. Accelerate Innovative Science
3. Be a Great Place to Work

A science-led value proposition

Distinctive R&D capabilities
Small molecules, biologics, protein engineering and innovative delivery devices, as well as new scientific modalities, new technologies and new biology.

171 projects in our development pipeline

Focus on three main therapy areas

Oncology
Our ambition is to provide cures for cancer in every form. We are following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential for cure.

Cardiovascular, Renal & Metabolism
Our mission is to protect the lives of people from the consequences of CVRM diseases. We are committed to their seamless management, improving patient outcomes and decreasing the mortality rate.

Respiratory & Immunology
We aim to transform the treatment of R&I diseases, with the bold ambition to eliminate preventable attacks and achieve durable remission or even cure for millions of people with these potentially devastating conditions.

Other Medicines and COVID-19
We have medicines and vaccines in other disease areas that have an important impact for patients. We are working to defeat the COVID-19 pandemic by advancing and accelerating the development of potential medicines.

Diversified portfolio of specialty and primary care medicines (Product Sales)

$10,850m 42% of total
2019: $8,667m
2018: $6,628m
Sales growth of 25% (25% at CER)

$7,096m 27% of total
2019: $6,906m
2018: $6,710m
Sales growth of 3% (5% at CER)

$5,357m 21% of total
2019: $5,391m
2018: $4,911m
Sales decline of 1% (6% at CER)

$2,587m 10% of total
2019: $2,601m
2018: $3,400m
Sales decline of 1% (0% at CER)

Key:
CER – constant exchange rate.
Figures in parentheses are used to represent negative numbers.
Terms used in this ‘at a glance’ are as defined within the Annual Report.
### Global strength, balanced presence across regions (Product Sales)

<table>
<thead>
<tr>
<th>Region</th>
<th>2019 Sales (m)</th>
<th>2018 Sales (m)</th>
<th>Year-over-Year Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emerging Markets</td>
<td>$8,679</td>
<td>$8,165</td>
<td>6%</td>
</tr>
<tr>
<td>US</td>
<td>$8,638</td>
<td>$7,747</td>
<td>12%</td>
</tr>
<tr>
<td>Europe</td>
<td>$5,059</td>
<td>$4,459</td>
<td>16%</td>
</tr>
<tr>
<td>Established Rest of World</td>
<td>$3,514</td>
<td>$3,303</td>
<td>6%</td>
</tr>
</tbody>
</table>

### Commitment to people

**A focus on inclusion and diversity, as well as life-long learning and development.**

<table>
<thead>
<tr>
<th>Number</th>
<th>Employees</th>
<th>Senior Roles Filled by Women</th>
<th>Employees</th>
<th>Employees</th>
<th>Employees</th>
<th>Employees</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>76,100</td>
<td>70,600</td>
<td>72,300</td>
<td>64,600</td>
<td>68,900</td>
<td>73,500</td>
</tr>
<tr>
<td>2018</td>
<td>76,100</td>
<td>64,600</td>
<td>69,600</td>
<td>62,700</td>
<td>69,400</td>
<td>69,400</td>
</tr>
</tbody>
</table>

### Commitment to society

**Improving access to healthcare, environmental protection and ethics and transparency, including delivering our Ambition Zero Carbon programme.**

<table>
<thead>
<tr>
<th>Priority</th>
<th>Access to Healthcare</th>
<th>Environmental Protection</th>
<th>Ethics and Transparency</th>
<th>2019 Dividends (m)</th>
<th>2019 R&amp;D Expenditure (m)</th>
<th>Credit Rating (Standard &amp; Poor’s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>$3,572</td>
<td>$5,991</td>
<td>BBB+</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Long term: CreditWatch Positive outlook</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>A3</td>
</tr>
</tbody>
</table>

### Capital allocation priorities

**After providing for investment in the business, supporting the progressive dividend policy and maintaining a strong, investment-grade credit rating, we keep under review potential investment in immediately earnings-accrue, value-enhancing opportunities.**

- **Dividends:** $3,572m (2019: $3,592m, 2018: $3,484m)
- **R&D expenditure (Reported):** $5,991m (2019: $6,059m, 2018: $5,932m)
- **Credit rating (Standard & Poor’s):** BBB+ (Long term: CreditWatch Positive outlook)
- **Credit rating (Moody’s):** A3 (Long term: Negative outlook)

### Comprehensive response to the COVID-19 pandemic

**Our response was consistent with our Values of following the science, putting patients first and doing the right thing.**

- Helped ensure the safety of patients and their continued access to care and medicines.
- Protected our employees and critical operations to ensure the continued supply of our medicines.
- Contributed to the process of scientific innovation to combat the virus.
- Contributed more broadly to society, including emergency relief.
Important information
This document contains certain statements extracted from the Annual Report and Form 20-F Information 2020 (Annual Report) for AstraZeneca PLC that are neither reported financial results nor other historical information. These statements are forward-looking statements, including within the meaning of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those disclosed in our forward-looking statements. For a description of factors that could affect future results, reference should be made to the full ‘Cautionary statement’ on page 284 of the Annual Report and to the section entitled ‘Risk’ from page 254. This information is provided solely for the convenience of current and future members of the Company and is not intended to satisfy any statutory and/or regulatory requirements in the UK or elsewhere. Accordingly, it should only be read in conjunction with the Annual Report. The Company, its subsidiaries, Directors and officers shall not be liable for the consequence of any action taken solely in reliance on the information contained in this document.